Q-omics provides the consensus-scored TMPO profile across patient tissues and cancer cell-line models. TMPO expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMPO is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TMPO protein abundance shows 33,147 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, BLCA, and GBM as cancer lineages where TMPO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMPO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMPO survival associations across molecular data types. TMPO RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMPO RNA expression–survival associations across cancer types. High TMPO expression shows unfavorable associations in MESO, KIRP, ACC and UVM, but favorable associations in UCS and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMPO RNA expression.
This table summarizes TMPO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMPO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMPO shows higher tumor expression in BLCA, STAD, LIHC, HNSC, COAD and LUSC. The BLCA box plot shows higher TMPO RNA expression in tumor versus normal tissue (log2 FC = +1.754, t-test p < 0.001).
This table shows molecular features associated with TMPO in patient tissues and cancer cell lines. In patient samples, TMPO shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMPO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
